GI Dynamics (ASX:GID) has been granted a trading halt by the ASX this afternoon pending the company's ENDO Trial.
GID is the developer of EndoBarrier®, the first endoscopically-delivered device therapy approved for the treatment of obese type 2 diabetes.
The halt will remain in place until the opening of trade on Friday 31st July 2015, or earlier if an announcement is made to the market.
GI Dynamics (ASX:GID) has been granted a trading halt by the ASX...
Add to My Watchlist
What is My Watchlist?